Hydralazine/isosorbide dinitrate
< Hydralazine
| Combination of | |
|---|---|
| Isosorbide dinitrate | Vasodilator |
| Hydralazine | Antihypertensive |
| Clinical data | |
| Trade names | Bidil |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| (what is this?) (verify) | |
Hydralazine/isosorbide dinitrate, sold under the brand name Bidil, is a fixed-dose combination medication used to treat self-identified Black people with congestive heart failure. It is a combination of hydralazine hydrochloride (an arteriolar vasodilator) and isosorbide dinitrate (a nitrate vasodilator).
The US Food and Drug Administration (FDA) approved medication to treat congestive heart failure in specifically self-identified Black patients. It provoked controversy as the first drug approved by the FDA marketed for a single racial-ethnic group.